| Literature DB >> 34625708 |
Stefano Cairo1, Vincent Goffin2, Laura Cheradame3,1, Ida Chiara Guerrera4, Julie Gaston3,1,5, Alain Schmitt6, Vincent Jung4, Nicolas Goudin7, Marion Pouillard3, Nina Radosevic-Robin8, Mauro Modesti9, Jean-Gabriel Judde1.
Abstract
STING (Stimulator of Interferon Genes) is an endoplasmic reticulum-anchored adaptor of the innate immunity best known to trigger pro-inflammatory cytokine expression in response to pathogen infection. In cancer, this canonical pathway can be activated by intrinsic or drug-induced genomic instability, potentiating antitumor immune responses. Here we report that STING downregulation decreases cell survival and increases sensitivity to genotoxic treatment in a panel of breast cancer cell lines in a cell-autonomous manner. STING silencing impaired DNA Damage Response (53BP1) foci formation and increased DNA break accumulation. These newly identified properties were found to be independent of STING partner cGAS and of its canonical pro-inflammatory pathway. STING was shown to partially localize at the inner nuclear membrane in a variety of breast cancer cell models and clinical tumor samples. Interactomics analysis of nuclear STING identified several proteins of the DNA Damage Response, including the three proteins of the DNA-PK complex, further supporting a role of STING in the regulation of genomic stability. In breast and ovarian cancer patients that received adjuvant chemotherapy, high STING expression is associated with increased risk of relapse. In summary, this study highlights an alternative, non-canonical tumor-promoting role of STING that opposes its well-documented function in tumor immunosurveillance.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34625708 DOI: 10.1038/s41388-021-02037-4
Source DB: PubMed Journal: Oncogene ISSN: 0950-9232 Impact factor: 9.867